It was the first centrally acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex.
On je bio prvi centralno delujući inhibitor holinesteraze odobren za tretman Alchajmerove bolesti, i bio je u prodaji pod imenom Cognex.